The next evolution of GLP-1: oral korglutide — a dual GLP-1/IGF-1 peptide for fat loss without muscle loss

This session focuses on Korglutide, a next-generation oral GLP-1 peptide (7 amino acids) developed by Caregen for weight loss and metabolic health.

In clinical evaluations, it has demonstrated effective weight reduction, along with a significant decrease in visceral fat while preserving lean muscle mass, supporting meaningful body recomposition rather than simple weight loss. This enables a more balanced and sustainable approach to metabolic management.

With its convenient once-daily oral format and completed FDA New Dietary Ingredient (NDI) registration, Korglutide is well positioned for scalable commercialization in the global nutraceutical market.